Clinical trials of CD47 blocking antibody in human cancer patients have not yielded ideal results. Here the authors show that USP2 stabilizes CD47 through deubiquitination, whereas USP2 inhibition enhances macrophage phagocytosis, reprograms tumor microenvironment and synergizes with anti-PD-1 treatment.
- Panpan Dai
- Yishuang Sun
- Jinfang Zhang